VolitionRx Limited announced data showing its NuQ blood tests have accurately detected more than 90% of lung cancer in a study of 73 patients.
VolitionRx Chief Scientific Officer, Dr. Jake Micallef, PhD, remarked, “The NuQ blood test not only differentiates lung cancer from healthy subjects but also from the common lung disease, COPD, which is related to tobacco consumption. The best current test for lung cancer is a scan that has high accuracy but does not distinguish well between cancerous and non-cancerous fibrous nodules in the lung, leading to a high false positive rate. Our interim data are exciting because they show both high sensitivity and very few false positives, indicating that a simple NuQ blood test, used alone or in conjunction with current standards, may detect lung cancer and distinguish it from other lung diseases.”
Cameron Reynolds, Chief Executive Officer of VolitionRx, added, “To be detecting more than 90% of cancers in this blinded trial is extremely exciting. VolitionRx’s studies in colorectal cancer, pancreatic cancer and now lung cancer have consistently shown that our Nucleosomics technology accurately detects cancers and is able to correctly distinguish among different diseases with a simple blood test. Using only a drop of blood, our NuQ tests aim to be affordable, patient friendly, and to be as easy to use as they are simple to perform on existing hospital laboratory instruments.”
VolitionRx expects to make full results of this ongoing lung cancer study available in 2016, as well as the results of another 600-subject lung cancer study conducted with the University Hospital Bonn in Germany.